The research company Cantargia announces that the study design and preclinical data for a Phase Ib/II study with the drug candidate nadunolimab will be presented at AACR 2026. The study, which is being conducted in collaboration with Mount Sinai in New York, targets patients with metastatic colorectal cancer who have not responded to chemotherapy.
LÄS MER